LENZ Therapeutics Company Insiders
| LENZ Stock | 33.58 0.15 0.44% |
LENZ Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding LENZ Therapeutics suggests that vertually all insiders are extremely bullish. LENZ Therapeutics employs about 13 people. The company is managed by 13 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-05-13 | James W Mccollum | Acquired 31332 @ 15.99 | View | ||
| 2024-03-21 | Ra Capital Management, L.P. | Acquired 998009 @ 15.03 | View |
Monitoring LENZ Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LENZ Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. LENZ Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2447) %, meaning that it created substantial loss on money invested by shareholders. LENZ Therapeutics' management efficiency ratios could be used to measure how well LENZ Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2025. Return On Capital Employed is likely to rise to -0.27 in 2025. Non Currrent Assets Other is likely to rise to about 1.7 M in 2025, whereas Total Assets are likely to drop slightly above 210.9 M in 2025.Common Stock Shares Outstanding is likely to drop to about 11.4 M in 2025
LENZ Therapeutics Workforce Comparison
LENZ Therapeutics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 333,128. LENZ Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
LENZ Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific LENZ Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on LENZ Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, LENZ Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
LENZ Therapeutics Notable Stakeholders
A LENZ Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as LENZ Therapeutics often face trade-offs trying to please all of them. LENZ Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting LENZ Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gerald Horn | Senior Founder | Profile | |
| Evert Schimmelpennink | CEO and Presidentident | Profile | |
| James McCollum | CoFounder Director | Profile | |
| Marvin Garrett | Senior Quality | Profile | |
| David Murphy | Senior Development | Profile | |
| Daniel CPA | Chief Officer | Profile | |
| Marc MD | Chief Officer | Profile | |
| Domenick Porfidia | Vice Sales | Profile | |
| David Choromanski | Vice Marketing | Profile | |
| Breianna Bowen | Vice Resources | Profile | |
| Kris Gambelin | Senior Operations | Profile | |
| Melissa Rosness | Senior Operations | Profile | |
| Shawn Olsson | Chief Officer | Profile |
About LENZ Therapeutics Management Performance
The success or failure of an entity such as LENZ Therapeutics often depends on how effective the management is. LENZ Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LENZ management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LENZ management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.27) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.23) |
Please note, the imprecision that can be found in LENZ Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of LENZ Therapeutics. Check LENZ Therapeutics' Beneish M Score to see the likelihood of LENZ Therapeutics' management manipulating its earnings.
LENZ Therapeutics Workforce Analysis
Traditionally, organizations such as LENZ Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare LENZ Therapeutics within its industry.LENZ Therapeutics Manpower Efficiency
Return on LENZ Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.8M | |
| Net Loss Per Executive | 3.8M | |
| Working Capital Per Employee | 15.5M | |
| Working Capital Per Executive | 15.5M |
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.